Topic

NVO

A collection of 2 issues

Novo Nordisk Shares Plunge 21% After Drug Trial Disappointment

Novo Nordisk shares tumble 21% after CagriSema trial results miss expectations, sparking retail investor interest. Discover the implications for NVO stock.

Novo Nordisk Loses $70 Billion in Market Cap Amid Obesity Drug Setback

Novo Nordisk experiences a $70 billion market cap loss following disappointing trial results for its obesity treatment. Discover the financial impact and future outlook.